Bringing innovative ADC and SMDC medicines to cancer patients around the world

As a biopharmaceutical company, CanWell Pharma Inc. is committed to accelerating the development and commercialization of first-in-class oncology products for targeted cancers to address highly unmet medical needs.

Founded in 2018, CanWell Pharma is led by several highly accomplished veterans who have an average of 25 years of experience in drug discovery and development in both U.S. and China biopharmaceutical industries. CanWell is dedicated to developing its proprietary first-in-class and best-in-class oncology products to address difficult-to-treat advanced cancers. CanWell is developing a rich R&D pipelines under our technology platforms.

Our Mission

Our mission at CanWell is to develop innovative treatments that harness the power of the immune system to fight cancer. We are devoted to leveraging the latest advances to further explore and develop a variety of innovative therapies. With a focus on collaboration, innovation and patient-centered care, we strive to be at the forefront of cancer therapy and bring new hope to patients and their families.

Antibody Drug Conjugate
ADC program includes StarLinker platform powered Dual-payload/drug, Multi-payload/drug ADCs and high DAR ADCs, as well as immune-stimulating drug conjugates using TLR agonists as payloads.
Read more
Small Molecule Drug Conjugate
Small Molecule Drug Conjugate (SMDC) platform with two clinical drug candidates CAN1012(TLR7 agonists),CAN2109 (ICD inducer) and multiple pre-clinical candidates
Read more